Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | AX. Zhu, YK Kang, CJ Yen, RS. Finn, PR. Galle, JM. Llovet, E Assenat, G Brandi, HY Lim, M Pracht, KM Rau, P Merle, K Motomura, I Ohno, B Daniele, D Shin, G Gerken, P Abada, Y Hsu, M Kudo | ||||||||||||
Title | REACH-2:A randomized,double-blind,placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib | ||||||||||||
|
|||||||||||||
URL | https://meetinglibrary.asco.org/record/159169/abstract | ||||||||||||
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 4003) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|